1. |
Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515. DOI: 10.1038/s41571-020-0352-8.
|
2. |
Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade[J]. J Clin Invest, 2015, 125(9): 3377-3383. DOI: 10.1172/JCI80012.
|
3. |
Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J]. Trends Mol Med, 2015, 21(1): 24-33. DOI: 10.1016/j.molmed.2014.10.009.
|
4. |
Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities[J]. Clin Cancer Res, 2016, 22(18): 4550-4555. DOI: 10.1158/1078-0432.CCR-15-2569.
|
5. |
Puwanant A, Isfort M, Lacomis D, et al. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition[J]. Neuromuscul Disord, 2019, 29(2): 127-133. DOI: 10.1016/j.nmd.2018.11.012.
|
6. |
Zhou L, Wei X. Ocular immune-related adverse eevents associated with iimmune checkpoint inhibitors in lung cancer[J/OL]. Front Immunol, 2021, 12: 701951[2021-08-04]. https://pubmed.ncbi.nlm.nih.gov/34504488/. DOI: 10.3389/fimmu.2021.701951.
|
7. |
Bomze D, MeirsonT, Hasan AliO, et al. Ocular aadverse events iinduced by immune checkpoint inhibitors: a ccomprehensive pharmacovigilance analysis[J]. Ocul Immunol Inflamm, 2022, 30(1): 191-197. DOI: 10.1080/09273948.2020.1773867.
|
8. |
Francis JH, JabenK, Santomasso BD, et al. Immune checkpoint inhibitor-associated optic neuritis[J]. Ophthalmology, 2020, 127(11): 1585-1589. DOI: 10.1016/j.ophtha.2020.05.003.
|
9. |
刘小伟, 王铮, 赵潺, 等. 肿瘤靶向治疗和免疫治疗眼科系统毒性反应的诊治[J]. 中国肺癌杂志, 2019, 22(10): 653-660. DOI: 10.3779/j.issn.1009-3419.2019.10.09.Liu XW, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of target therapy and immune checkpoint inhibitor therapy[J]. Chin J Lung Cancer, 2019, 22(10): 653-660. DOI: 10.3779/j.issn.1009-3419.2019.10.09.
|
10. |
汪龙, 周宁宁, 王慕华, 等. 免疫检查点抑制剂致神经系统不良反应[J]. 中国医院药学杂志, 2018, 38(16): 1735-1738. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.16.14.Wang L, Zhou NN, Wang MH, et al. Neurological adverse effect induced by immune checkpoint blockades[J]. Chin Hosp Pharm J, 2018, 38(16): 1735-1738. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.16.14.
|
11. |
Park RB, JainS, Han H, et al. Ocular surface disease associated with immune checkpoint inhibitor therapy[J]. Ocul Surf, 2021, 20: 115-129. DOI: 10.1016/j.jtos.2021.02.004.
|
12. |
Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation--a case series and review of the literature[J]. Ocul Immunol Inflamm, 2016, 24(2): 140-146. DOI: 10.3109/09273948.2014.1001858.
|
13. |
Mantopoulos D, KendraKL, Letson AD, et al. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma[J]. JAMA Ophthalmol, 2015, 133(8): 965-967. DOI: 10.1001/jamaophthalmol.2015.1128.
|
14. |
Crews J, Agarwal A, Jack L, et al. Ipilimumab-associated retinopathy[J]. Ophthalmic Surg Lasers Imaging Retina, 2015, 46(6): 658-660. DOI: 10.3928/23258160-20150610-10.
|
15. |
Alba-Linero C, Alba E. Ocular side effects of checkpoint inhibitors[J]. SurvOphthalmol, 2021, 66(6): 951-959. DOI: 10.1016/j.survophthal.2021.01.001.
|
16. |
Wu SZ, MasurkarAV, BalcerLJ. Afferent and efferent visual markers of Alzheimer's disease: a review and update in early stage disease[J/OL]. Front Aging Neurosci, 2020, 12: 572337[2020-09-11]. https://pubmed.ncbi.nlm.nih.gov/33061906/. DOI: 10.3389/fnagi.2020.572337.
|
17. |
Yu CW, Yau M, Mezey N, et al. Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review[J]. Eye Brain, 2020, 12: 139-167. DOI: 10.2147/EB.S277760.
|
18. |
Wilhelm H, Schabet M. The diagnosis and treatment of optic neuritis[J]. DtschArztebl Int, 2015, 112(37): 616-625. DOI: 10.3238/arztebl.2015.0616.
|
19. |
Shimada T, Hoshino Y, Tsunemi T, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab[J/OL]. Mult Scler Relat Disord, 2020, 37: 101447[2019-10-14]. https://pubmed.ncbi.nlm.nih.gov/31655267/. DOI: 10.1016/j.msard.2019.101447.
|
20. |
Hirano S, Kojima A, Nakayama Y, et al. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study[J]. BMC Neurol, 2022, 22(1): 483. DOI: 10.1186/s12883-022-02987-6.
|
21. |
Khimani K, Patel SP, Whyte A, et al. Case report: neuromyelitis optica after treatment of uveal melanoma with Nivolumab and Ipilimumab[J/OL]. Front Oncol, 2022, 12: 806501[2022-03-23]. https://pubmed.ncbi.nlm.nih.gov/35402220/. DOI: 10.3389/fonc.2022.806501.
|
22. |
Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4[J]. Arthritis Rheumatol, 2014, 66(3): 768-769. DOI: 10.1002/art.38282.
|
23. |
Micaily I CM. An unknown reaction to pembrolizumab: giant cell arteritis[J]. Ann Oncol, 2017, 28: 2621–2622. DOI: 10.1093/annonc/mdx306.
|
24. |
Hid Cadena R, AbdulahadWH, HospersGAP, et al. Checks and balances in autoimmune vasculitis[J/OL]. Front Immunol, 2018, 9: 315[2018-02-22]. https://pubmed.ncbi.nlm.nih.gov/29520282/. DOI: 10.3389/fimmu.2018.00315.
|
25. |
Betrains AE, Blockmans DE. Immune checkpoint inhibitor-associated polymyalgia rheumatica/giant cell arteritis occurring in a patient after treatment with nivolumab[J]. J Clin Rheumatol, 2021, 27(8S): S555-556. DOI: 10.1097/RHU.0000000000001012.
|
26. |
Chow KL, Perju-Dumbrava L, Malhotra A. Giant cell arteritis secondary to combined nivolumab and ipilimumab in metastatic pleural mesothelioma[J]. Neurol Asia, 2020: 25.
|
27. |
Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma[J]. J Ophthalmic Inflamm Infect, 2016, 6(1): 14. DOI: 10.1186/s12348-016-0082-3.
|
28. |
Pula JH, Yuen CA. Eyes and stroke: the visual aspects of cerebrovascular disease[J]. Stroke Vasc Neurol, 2017, 2(4): 210-220. DOI: 10.1136/svn-2017-000079.
|
29. |
Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque[J]. Circulation, 2020, 142(24): 2299-2311. DOI: 10.1161/CIRCULATIONAHA.120.049981.
|
30. |
Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study[J]. J Immunother Cancer, 2019, 7(1): 134. DOI: 10.1186/s40425-019-0617-x.
|
31. |
Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 319. DOI: 10.1186/s40425-019-0774-y.
|
32. |
Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan[J]. Neurology, 2017, 89(11): 1127-1134. DOI: 10.1212/WNL.0000000000004359.
|
33. |
Pathak R, Katel A, Massarelli E, et al. Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases[J]. Oncologist, 2021, 26(12): 1052-1061. DOI: 10.1002/onco.13931.
|
34. |
Onda A, Miyagawa S, Takahashi N, et al. Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy[J]. Intern Med, 2019, 58(11): 1635-1638. DOI: 10.2169/internalmedicine.1956-18.
|
35. |
Stelmachowska-Banaś M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review[J]. Endocr Connect, 2020, 9(10): 207-228. DOI: 10.1530/EC-20-0342.
|
36. |
Peiffert M, Cugnet-Anceau C, Dalle S, et al. Graves' disease during immune checkpoint inhibitor therapy (a case series and literature review)[J/OL]. Cancers (Basel), 2021, 13(8): 1944[2021-04-17]. https://pubmed.ncbi.nlm.nih.gov/33920721/. DOI: 10.3390/cancers13081944.
|
37. |
Chau CYC, Shih KC, Chow LLW, et al. Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with coexisting thyroid eye disease[J]. Ophthalmol Ther, 2021, 10(1): 5-12. DOI: 10.1007/s40123-020-00317-y.
|
38. |
Wladis EJ, Kambam ML. Ophthalmic complications of immune checkpoint inhibitors[J]. Orbit, 2022, 41(1): 28-33. DOI: 10.1080/01676830.2020.1867192.
|
39. |
Moreira A, Loquai C, Pfohler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors[J]. Eur J Cancer, 2019, 106: 12-23. DOI: 10.1016/j.ejca.2018.09.033.
|
40. |
Kang KH, Grubb W, Sawlani K, et al. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management[J]. Am J Otolaryngol, 2018, 39(5): 642-645. DOI: 10.1016/j.amjoto.2018.06.003.
|
41. |
Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies[J]. JAMA Neurol, 2017, 74(10): 1216-1222. DOI: 10.1001/jamaneurol.2017.1912.
|
42. |
Mancone S, Lycan T, Ahmed T, et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review[J]. J Neurol, 2018, 265(7): 1636-1642. DOI: 10.1007/s00415-018-8890-z.
|
43. |
Hassanzadeh B, DeSanto J, Kattah JC. Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management[J]. Neuroophthalmology, 2018, 42(3): 176-181. DOI: 10.1080/01658107.2017.1368090.
|
44. |
Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network[J/OL]. PLoS One, 2013, 8(1): e53745[2013-01-14]. https://pubmed.ncbi.nlm.nih.gov/23341990/. DOI: 10.1371/journal.pone.0053745.
|
45. |
Siegel CH, Finn RS, Ho MG. Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma[J]. Mayo Clin Proc, 2018, 93(4): 540-541. DOI: 10.1016/j.mayocp.2018.01.001.
|
46. |
Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade[J]. J Neuroophthalmol, 2021, 41(4): 519-530. DOI: 10.1097/wno.0000000000001148.
|
47. |
Tang L, Wang J, Lin N, et al. Immune checkpoint inhibitor-associated colitis: from mmechanism to management[J/OL]. Front Immunol, 2021, 12: 800879[2021-12-21]. https://pubmed.ncbi.nlm.nih.gov/34992611/. DOI: 10.3389/fimmu.2021.800879.
|
48. |
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA 4 control over Foxp3 regulatory T cell function[J]. Science, 2008, 322(5899): 271-275. DOI: 10.1126/science.1160062.
|
49. |
Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8): 473-486. DOI: 10.1038/nrclinonc.2016.58.
|
50. |
Zhou YW, Xu Q, Wang Y, et al. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management[J]. Int J Ophthalmol, 2022, 15(4): 646-656. DOI: 10.18240/ijo.2022.04.19.
|
51. |
Nieto-Aristizábal II, Mera JJ, Giraldo JD, et al. From ocular immune privilege to primary autoimmune diseases of the eye[J/OL]. Autoimmun Rev, 2022, 21(8): 103122[2022-06-04]. https://pubmed.ncbi.nlm.nih.gov/35667621/. DOI: 10.1016/j.autrev.2022.103122.
|
52. |
Zhao Z, Zhang C, Zhou L, et al. Immune checkpoint inhibitors and neurotoxicity[J]. Current Neuropharmacology, 2021, 19(8): 1246-1263. DOI: 10.2174/1570159x19666201230151224.
|
53. |
徐全刚. 与肿瘤相关的视神经病变[J]. 中国眼耳鼻喉科杂志, 2022, 22(1): 3-6. DOI: 10.14166/j.issn.1671-2420.2022.01.002.Xu QG. Tumor-associated optic neuropathy[J]. Chin J Ophthalmol and Otorhinolaryngol, 2022, 22(1): 3-6. DOI: 10.14166/j.issn.1671-2420.2022.01.002.
|